Study of Tumor Tissue From Patients With Melanoma Treated on Clinical Trial EST-1690
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00937781|
Recruitment Status : Completed
First Posted : July 13, 2009
Last Update Posted : May 17, 2017
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This research study is looking at tumor tissue samples from patients with melanoma treated on clinical trial EST-1690.
|Condition or disease||Intervention/treatment|
|Melanoma (Skin)||Genetic: RNA analysis Genetic: gene expression analysis Genetic: microarray analysis Genetic: polymerase chain reaction Other: immunohistochemistry staining method Other: laboratory biomarker analysis|
- To validate the prognostic role of several biomarkers suggested by gene expression profiling and tissue microarray (TMA) studies (e.g., NCOA3, SPP1, and RGS1) on the outcome associated with melanoma in the EST-1690 cohort using IHC analysis.
- To examine the potential predictive role of such biomarkers in patients undergoing adjuvant interferon alfa therapy.
- To analyze the correlation between the intensity of biomarker expression and survival of this cohort both in the observation and in the interferon-treated groups.
- To examine the prognostic role of these biomarkers on the outcome associated with melanoma in the EST-1690 cohort using quantitative-PCR.
- To isolate RNA from the primary specimens from patients enrolled in the EST-1690 cohort to assess the expression of genes suggested by cDNA microarray and IHC analyses (e.g., NCOA3, SPP1, and RGS1) as prognostic or predictive markers.
OUTLINE: Samples from the EST-1690 cohort are obtained and analyzed for several biomarkers (i.e., NCOA3, SPP1, and RGS1) via immunohistochemistry and quantitative PCR. RNA is isolated from the specimens to assess gene expression via quantitative PCR.
|Study Type :||Observational|
|Actual Enrollment :||307 participants|
|Official Title:||Molecular Prognostic Factor Analysis in Melanoma|
|Actual Study Start Date :||February 8, 2011|
|Actual Primary Completion Date :||August 8, 2011|
|Actual Study Completion Date :||August 8, 2011|
- Prognostic role of several biomarkers on the outcome associated with melanoma using IHC [ Time Frame: 1 month ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00937781
|Study Chair:||Mohammed Kashani-Sabet, MD||University of California, San Francisco|